Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas

Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase (FT). FT catalyzes the post-translational attachment of farnesyl groups to signaling proteins that are required for localization to cell membranes. Although all RAS isoforms are FT substrates, only HRAS is exclusively depen...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Mol Cancer Ther
Hauptverfasser: Gilardi, Mara, Wang, Zhiyong, Proietto, Marco, Chillà, Anastasia, Calleja-Valera, Juan Luis, Goto, Yusuke, Vanoni, Marco, Janes, Matthew R., Mikulski, Zbigniew, Gualberto, Antonio, Molinolo, Alfredo A., Ferrara, Napoleone, Gutkind, J. Silvio, Burrows, Francis
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484242/
https://ncbi.nlm.nih.gov/pubmed/32727882
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-19-0958
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge